Immunotoxin for Treating Small Cell Lung Cancer
Author Information
Author(s): E.J. Wawrzynczak, U. Zangemeister-Wittke, R. Waibel, R.V. Henry, G.D. Parnell, A.J. Cumber, M. Jones, R.A. Stahel
Primary Institution: Institute of Cancer Research, Sutton, Surrey, UK and University Hospital, Zurich, Switzerland
Hypothesis
Can an abrin A chain immunotoxin effectively target and treat human small cell lung cancer?
Conclusion
The study found that the immunotoxin significantly delayed tumor growth in mice with small cell lung cancer.
Supporting Evidence
- The immunotoxin retained the cell-binding capacity of the antibody and the ribosome-inactivating activity of the A chain.
- In cytotoxicity assays, the immunotoxin inhibited protein synthesis in cancer cells significantly.
- A single injection of the immunotoxin delayed tumor growth in mice for 7 to 10 days.
Takeaway
Researchers created a special medicine that can help fight a type of lung cancer by using a toxin attached to an antibody that targets cancer cells.
Methodology
The immunotoxin was synthesized, purified, and tested for cytotoxic effects in tissue culture and in mice with tumor xenografts.
Limitations
The anti-tumor effects were modest and further studies are needed to optimize treatment.
Participant Demographics
Nude mice were used for the experiments.
Statistical Information
P-Value
0.05-0.02
Statistical Significance
p=0.05-0.02
Want to read the original?
Access the complete publication on the publisher's website